Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging study
Mark C. Genovese(Eli Lilly (United States)), Andrew R. Baldassare(Ophthalmology Consultants), Jeffrey Kaine(Sarasota University), Greg Spaniolo, Robert G. Trapp, Edward J. Fudman(Baylor College of Medicine), Mitchell B. Lowenstein, Michael Kohen, José Del Giudice(Altoona Arthritis and Osteoporosis Center), Joy Schechtman, Nadera Sweiss(University of Illinois Chicago), Wolfgang Dummer(BioMarin (United States)), Sheila Gujrathi(Bristol-Myers Squibb (Germany))
Cited by 206
Related Papers
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
|New England Journal of Medicine|2005|1.2k
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
|Arthritis & Rheumatism|2002|733